KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Capital Leases (2016)

Rigel Pharmaceuticals (RIGL) has 4 years of Capital Leases data on record, last reported at $238000.0 in Q4 2016.

  • For Q4 2016, Capital Leases fell 93.12% year-over-year to $238000.0; the TTM value through Dec 2016 reached $238000.0, down 93.12%, while the annual FY2016 figure was $238000.0, 93.12% down from the prior year.
  • Capital Leases reached $238000.0 in Q4 2016 per RIGL's latest filing, down from $1.1 million in the prior quarter.
  • Across five years, Capital Leases topped out at $6.5 million in Q4 2014 and bottomed at $238000.0 in Q4 2016.
  • Average Capital Leases over 3 years is $3.4 million, with a median of $3.5 million recorded in 2015.
  • Peak YoY movement for Capital Leases: tumbled 46.49% in 2015, then crashed 93.12% in 2016.
  • A 3-year view of Capital Leases shows it stood at $6.5 million in 2014, then plummeted by 46.49% to $3.5 million in 2015, then plummeted by 93.12% to $238000.0 in 2016.
  • Per Business Quant database, its latest 3 readings for Capital Leases were $238000.0 in Q4 2016, $1.1 million in Q3 2016, and $1.9 million in Q2 2016.